iBio
IBIO
IBIO
77 hedge funds and large institutions have $25M invested in iBio in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
47% less call options, than puts
Call options by funds: $367K | Put options by funds: $690K
48% less capital invested
Capital invested by funds: $47.6M → $25M (-$22.6M)
Holders
77
Holding in Top 10
–
Calls
$367K
Puts
$690K
Top Buyers
| 1 | +$134K | |
| 2 | +$124K | |
| 3 | +$120K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$101K |
| 5 |
Barclays
London,
United Kingdom
|
+$95.5K |
Top Sellers
| 1 | -$181K | |
| 2 | -$161K | |
| 3 | -$146K | |
| 4 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$88.2K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$66.7K |